Canaccord gives latest target for LABS of $2.50 :) Canaccord Genuity Raises Medipharm Labs Price Target To C$2.50 October 6, 2020 1:29 PM Justin Young 0 Comments Analyst Estimate, Medipharm Labs k Share N Tweet s Share On Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European pharmaceutical company STADA. Under the agreement, Medipharm will supply GMP certified medical cannabis, manufacturing, logistics, and regulatory support to STADA. At the same time, STADA will be responsible for commercializing cannabis products, which will initially be sold in Germany. STADA CEO Peter Goldschmidt commented in yesterdays release, This partnership with MediPharm demonstrates STADAs ambition to be the go-to-partner for Generics, Consumer Health, and Specialty Products. With MediPharm, we are collaborating with a very strong partner in the Medical Cannabis field. This morning, Canaccord Genuitys Matt Bottomley raised his 12-month price target on MediPharm Labs to C$2.50 from C$2.25 and reiterated his Speculative Buy rating on the stock. Bottomley says, in our view, this announcement validates LABS strategic focus as a pharma-quality API provider and go-to contract manufacturing partner within international medical cannabis markets by an established and reputable global pharmaceutical provider.